Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

被引:69
作者
Arora, Prerna [1 ,2 ]
Kempf, Amy [1 ,2 ]
Nehlmeier, Inga [1 ,2 ]
Schulz, Sebastian R. [3 ]
Cossmann, Anne [4 ]
Stankov, Metodi V. [4 ,5 ]
Jaeck, Hans-Martin [3 ]
Behrens, Georg M. N. [4 ,5 ]
Pohlmann, Stefan [1 ,2 ]
Hoffmann, Markus [1 ,2 ]
机构
[1] German Primate Ctr, Infect Biol Unit, D-37077 Gottingen, Germany
[2] Georg August Univ Gottingen, Fac Biol & Psychol, Gottingen, Germany
[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Internal Med 3, Div Mol Immunol, Erlangen, Germany
[4] Hannover Med Sch, Dept Rheumatol & Immunol, Hannover, Germany
[5] German Ctr Infect Res, Partner Site Hannover Braunschweig, Hannover, Germany
关键词
D O I
10.1016/S1473-3099(22)00422-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
引用
收藏
页码:1117 / 1118
页数:3
相关论文
共 8 条
[1]  
[Anonymous], 2022, BIORXIV, DOI [10.1101/2022.04.30.489997, DOI 10.1101/2022.04.30.489997]
[2]   Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3 [J].
Arora, Prerna ;
Zhang, Lu ;
Rocha, Cheila ;
Sidarovich, Anzhalika ;
Kempf, Amy ;
Schulz, Sebastian ;
Cossmann, Anne ;
Manger, Bernhard ;
Baier, Eva ;
Tampe, Bjoern ;
Moerer, Onnen ;
Dickel, Steffen ;
Dopfer-Jablonka, Alexandra ;
Jaeck, Hans-Martin ;
Behrens, Georg M. N. ;
Winkler, Martin S. ;
Poehlmann, Stefan ;
Hoffmann, Markus .
LANCET INFECTIOUS DISEASES, 2022, 22 (06) :766-767
[3]  
Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]
[4]   The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic [J].
Hoffmann, Markus ;
Krueger, Nadine ;
Schulz, Sebastian ;
Cossmann, Anne ;
Rocha, Cheila ;
Kempf, Amy ;
Nehlmeier, Inga ;
Graichen, Luise ;
Moldenhauer, Anna-Sophie ;
Winkler, Martin S. ;
Lier, Martin ;
Dopfer-Jablonka, Alexandra ;
Jaeck, Hans-Martin ;
Behrens, Georg M. N. ;
Poehlmann, Stefan .
CELL, 2022, 185 (03) :447-+
[5]  
Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4
[6]  
Schmidt Fabian, 2020, J Exp Med, V217, DOI [10.1101/2020.06.08.140871, 10.1084/jem.20201181]
[7]  
Westendorf K, 2022, CELL REP, V39, DOI [10.1016/j.celrep.2022.110812, 10.1101/2021.04.30.442182]
[8]  
Yamasoba D, 2022, LANCET INFECT DIS, V22, P942, DOI 10.1016/S1473-3099(22)00365-6